 Engeline, a flavonoid glycoside, has been shown to be effective at reducing mitochondrial dysfunction and inflammation in Huntington's disease, HD, a genetic disorder characterized by progressive degeneration of the brain's motor and cognitive functions. However, its low solubility and poor permeability limit its ability to reach the target site. This study proposes a theoretical formulation of Engeline nanostructured lipid nanocarriers to overcome these limitations and enhance its delivery and bioavailability. The proposed formulation could offer a similar composition to the natural lipids found in the body, allowing for free transit over the blood-brain barrier and increasing the bioavailability of Engeline, potentially leading to a cure or prevention of HD. This article was authored by Smurdi, Madhav Singla, Sohrab Gupta, and others.